clinical trial · NCT06781567
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
HitGen Inc.·phase2·recruiting·n = 140
Adenoid Cystic CarcinomaHead and Neck CancerHG146
brief summary
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
started
Dec 13, 2024
primary completion
Dec 31, 2028
completion
Jun 30, 2029
last updated
Mar 14, 2025
official title
A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants with Recurrent or Metastatic Adenoid Cystic Carcinoma.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol